azacitidin pharmascience 25 mg/ml pulver zur herstellung einer injektionssuspension
pharmascience international limited (8141906) - azacitidin - pulver zur herstellung einer injektionssuspension - 25 mg/ml - teil 1 - pulver zur herstellung einer injektionssuspension; azacitidin (33486) 25 milligramm
bosentan pharmascience 62,5 mg filmtabletten
pharmascience international limited (8141906) - filmtablette - 62,5 mg
bosentan pharmascience 125 mg filmtabletten
pharmascience international limited (8141906) - filmtablette - 125 mg
abirateron pharmascience 500 mg filmtabletten
pharmascience international limited (8141906) - filmtablette - 500 mg
bimatoprost pi ltd. 0,1 mg/ml augentropfen augentropfen, lösung
pharmascience international limited - bimatoprost - augentropfen, lösung - bimatoprost 0.1mg
latanoprost / timolol pi ltd. 50 mikrogramm/ml + 5 mg/ml augentropfen
pharmascience international limited - latanoprost, timololmaleat - augentropfen - latanoprost 0.05mg; timololmaleat 6.8mg
duloxetin axiromed 60 mg magensaftresistente hartkapseln
medical valley invest ab beiname: axiromed, xiromed (8160803) - duloxetinhydrochlorid - magensaftresistente hartkapsel - teil 1 - magensaftresistente hartkapsel; duloxetinhydrochlorid (31791) 67,22 milligramm
duloxetin axiromed 30 mg magensaftresistente hartkapseln
medical valley invest ab beiname: axiromed, xiromed (8160803) - duloxetinhydrochlorid - magensaftresistente hartkapsel - teil 1 - magensaftresistente hartkapsel; duloxetinhydrochlorid (31791) 33,61 milligramm
dasatinib accord
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.